XOMAP Key Statistics, Chart & Performance
The current stock price of XOMAP is 26.62 USD. In the past month the price decreased by -0.45%. In the past year, price increased by 3.62%.
XOMAP Latest News, Press Relases and Analysis
XOMAP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About XOMAP
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Company Info
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
2200 Powell Street, Suite 310
Emeryville CALIFORNIA US
Employees: 13
Phone: 15102047200
XOMA ROYALTY CORP - XOMA 8 5/8 PERP / XOMAP FAQ
What does XOMA ROYALTY CORP - XOMA 8 5/8 PERP do?
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
What is the current price of XOMAP stock?
The current stock price of XOMAP is 26.62 USD. The price increased by 0.49% in the last trading session.
Does XOMAP stock pay dividends?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) has a dividend yield of 8.1%. The yearly dividend amount is currently 0.47.
What is the ChartMill technical and fundamental rating of XOMAP stock?
XOMAP has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for XOMA ROYALTY CORP - XOMA 8 5/8 PERP?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for XOMA ROYALTY CORP - XOMA 8 5/8 PERP?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) has a market capitalization of 329.56M USD. This makes XOMAP a Small Cap stock.
Can you provide the short interest for XOMAP stock?
The outstanding short interest for XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is 0.03% of its float.
XOMAP Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to XOMAP. When comparing the yearly performance of all stocks, XOMAP turns out to be only a medium performer in the overall market: it outperformed 56.82% of all stocks.
XOMAP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to XOMAP. While XOMAP is still in line with the averages on profitability rating, there are concerns on its financial health.
XOMAP Financial Highlights
Over the last trailing twelve months XOMAP reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 135.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.93% | ||
| ROE | -19.17% | ||
| Debt/Equity | 1.11 |
XOMAP Forecast & Estimates
10 analysts have analysed XOMAP and the average price target is 53.86 USD. This implies a price increase of 102.34% is expected in the next year compared to the current price of 26.62.
For the next year, analysts expect an EPS growth of 126.86% and a revenue growth 85% for XOMAP